Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher P Denton

Showing results (11-20 of 484) with videos related to

Pageof 49
Sort By:
Arthritis Research & Therapy|March 29, 2019
Cause or effect? Interpreting emerging evidence for dysbiosis in systemic sclerosisChristopher P Denton, Charles Murray
Seminars in Respiratory and Critical Care Medicine|May 29, 2019
Pulmonary Complications of Connective Tissue DiseaseAthol Wells, Christopher P Denton
Clinical and Experimental Rheumatology|January 22, 2026
Reply to the comment on: Impact of early immuno-suppressive therapy on pulmonary arterial hypertension in systemic sclerosis: a single-centre real-world studyStefano Rodolfi, Christopher P Denton
Arthritis & Rheumatology (Hoboken, N.J.)|February 3, 2021
Combining Data Sets as Well as Therapies Shows Improved Outcome in Connective Tissue Disease-Associated Pulmonary HypertensionChristopher P Denton, Julia Spierings
Lancet (London, England)|April 18, 2017
Systemic sclerosisChristopher P Denton, Dinesh Khanna
The Lancet. Rheumatology|January 27, 2024
Rational repurposing of tocilizumab for treatment of lung fibrosis in systemic sclerosisChristopher P Denton, Dinesh Khanna
Best Practice & Research. Clinical Rheumatology|June 11, 2010
Evidence-based management of rapidly progressing systemic sclerosisDinesh Khanna, Christopher P Denton
Current Opinion in Rheumatology|September 9, 2022
Scleroderma autoantibodies in guiding monitoring and treatment decisionsShivani Shah, Christopher P Denton
The Lancet. Respiratory Medicine|May 20, 2021
Integrating new therapies for systemic sclerosis-associated lung fibrosis in clinical practiceDinesh Khanna, Christopher P Denton
Best Practice & Research. Clinical Rheumatology|May 26, 2004
Scleroderma--clinical and pathological advancesChristopher P Denton, Carol M Black
Pageof 49

Showing results (11-20 of 484) with videos related to

Sort By:
Pageof 49
Arthritis Research & Therapy|March 29, 2019
Cause or effect? Interpreting emerging evidence for dysbiosis in systemic sclerosisChristopher P Denton, Charles Murray
Seminars in Respiratory and Critical Care Medicine|May 29, 2019
Pulmonary Complications of Connective Tissue DiseaseAthol Wells, Christopher P Denton
Clinical and Experimental Rheumatology|January 22, 2026
Reply to the comment on: Impact of early immuno-suppressive therapy on pulmonary arterial hypertension in systemic sclerosis: a single-centre real-world studyStefano Rodolfi, Christopher P Denton
Arthritis & Rheumatology (Hoboken, N.J.)|February 3, 2021
Combining Data Sets as Well as Therapies Shows Improved Outcome in Connective Tissue Disease-Associated Pulmonary HypertensionChristopher P Denton, Julia Spierings
Lancet (London, England)|April 18, 2017
Systemic sclerosisChristopher P Denton, Dinesh Khanna
The Lancet. Rheumatology|January 27, 2024
Rational repurposing of tocilizumab for treatment of lung fibrosis in systemic sclerosisChristopher P Denton, Dinesh Khanna
Best Practice & Research. Clinical Rheumatology|June 11, 2010
Evidence-based management of rapidly progressing systemic sclerosisDinesh Khanna, Christopher P Denton
Current Opinion in Rheumatology|September 9, 2022
Scleroderma autoantibodies in guiding monitoring and treatment decisionsShivani Shah, Christopher P Denton
The Lancet. Respiratory Medicine|May 20, 2021
Integrating new therapies for systemic sclerosis-associated lung fibrosis in clinical practiceDinesh Khanna, Christopher P Denton
Best Practice & Research. Clinical Rheumatology|May 26, 2004
Scleroderma--clinical and pathological advancesChristopher P Denton, Carol M Black
Pageof 49